glp 1 agonist australia Clinical Practice Recommendation On Periprocedural Use Of GLP-1/GIP Receptor Agonists (June 2024) RACGP - Unregulated GLP-1 access

In 2014, the FDA approved the first of these drugs specifically for weight loss for people with a BMI of 30 and above or a BMI of at least 27 with one weight-related comorbid disease, which affects more than half the U.S

Tirzepatide came off the FDAs official drug shortage list in December 2024, and semaglutide followed in February 2025, eliminating the legal pathway that allowed compounding pharmacies to produce copies of the drugs

doi: 10.1016/j.nut.2019.06.005 [DOI] [PubMed] [Google Scholar] 207

In this system, the quality of systematic reviews included RCTs set to be high and downgraded by 5 criteria assessment: (1) risk of bias in individual studies, (2) inconsistency of results between studies, (3) indirectness of evidence, (4) imprecision, and (5) publication bias

the Take-Away A new class of diabetes and weight-loss drugs is drawing attention from researchers, and the early data on opioid addiction may be the most compelling signal yet